WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the completion of national phase filings for its istaroxime patent applications across key global markets, including the United States, Germany, France, Italy, Japan, and China. This move marks a significant step in the company’s strategy to bolster its intellectual property portfolio related to the treatment of cardiogenic shock.
The patent, titled “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGENIC SHOCK AND CARDIOGENIC SHOCK,” is registered under application No. 18/858,086. It underscores Windtree’s commitment to advancing treatments for patients experiencing cardiogenic shock, a critical condition characterized by inadequate circulation due to heart failure.
Craig Fraser, Chairman and CEO of Windtree, emphasized the importance of expanding their patent estate. “Windtree continues to prepare for the potential of istaroxime in treating cardiogenic shock patients by expanding and strengthening our patent estate,” he noted. Fraser highlighted that the unique aspects of istaroxime are central to their intellectual property strategy, which has been supported by positive clinical development outcomes.
Istaroxime is a novel dual-mechanism therapy aimed at enhancing both systolic and diastolic heart function. It functions as a positive inotropic agent, increasing heart muscle contractility while simultaneously promoting myocardial relaxation through the activation of the SERCA2a calcium pump. Clinical trials have shown that istaroxime significantly improves cardiac performance and blood pressure without raising heart rates or causing rhythm disturbances.
Windtree Therapeutics’ latest patent filings are poised to reinforce its position in the cardiovascular treatment landscape, as the company continues to push forward with its innovative solutions for heart failure management.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.